Clinical Trial Update: CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CCI-779 (temsirolimus) in patients with recurrent or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• CCI-779 (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 2 | Status: COMPLETED | Results posted: 2014-02-11